Provided by Tiger Fintech (Singapore) Pte. Ltd.

Ocular Therapeutix

7.71
-0.1900-2.41%
Post-market: 7.710.00000.00%16:05 EDT
Volume:1.71M
Turnover:13.22M
Market Cap:1.23B
PE:-6.31
High:7.96
Open:7.79
Low:7.62
Close:7.90
Loading ...

Ocular Therapeutix Inc : H.c. Wainwright Raises Target Price to $15 From $14

THOMSON REUTERS
·
15 Nov 2024

Ocular Therapeutix Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
15 Nov 2024

Ocular Therapeutix: Strategic Progress and Promising Pipeline Drive Buy Rating

TIPRANKS
·
15 Nov 2024

Ocular Therapeutix Inc (OCUL) Q3 2024 Earnings Call Highlights: Strong Financial Position and ...

GuruFocus.com
·
15 Nov 2024

Ocular Therapeutix Reports Q3 2024 Financial Results

TIPRANKS
·
15 Nov 2024

Ocular Therapeutix Inc : TD Cowen Raises Target Price to $14 From $11

THOMSON REUTERS
·
15 Nov 2024

Ocular Therapeutix’s Clinical Progress and Strategic Trials Drive Buy Rating

TIPRANKS
·
14 Nov 2024

Ocular Therapeutix Inc reports results for the quarter ended September 30 - Earnings Summary

Reuters
·
14 Nov 2024

Ocular Therapeutix: Q3 Earnings Snapshot

Associated Press Finance
·
14 Nov 2024

Ocular Therapeutix Q3 Net Loss Narrows as Revenue Increases

MT Newswires Live
·
14 Nov 2024

Ocular Therapeutix's Cash Balance Of $427.2M As Of September 30, 2024, Expected To Fund Operations Into 2028

Benzinga
·
14 Nov 2024

Ocular Therapeutix Q3 2024 GAAP EPS $(0.22) Beats $(0.24) Estimate, Sales $15.43M Miss $17.14M Estimate

Benzinga
·
14 Nov 2024

BRIEF-Ocular Therapeutix Q3 EPS USD -0.22 Vs. IBES Estimate USD -0.24

Reuters
·
14 Nov 2024

Ocular Therapeutix Inc: Cash Balance of $427.2M as of September 30, 2024, Expected to Fund Operations Into 2028

THOMSON REUTERS
·
14 Nov 2024

Ocular Therapeutix Inc: Sol-1 Expected to Be Fully Randomized by Ye 2024 With Topline Data Expected in Q4 2025

THOMSON REUTERS
·
14 Nov 2024

Ocular Therapeutix Q3 EPS USD -0.22 VS. Ibes Estimate USD -0.24

THOMSON REUTERS
·
14 Nov 2024

Ocular Therapeutix Q3 Basic EPS USD -0.22

THOMSON REUTERS
·
14 Nov 2024

Ocular Therapeutix Q3 Product Revenue USD 15.347 Million

THOMSON REUTERS
·
14 Nov 2024

Harrow (HROW) Reports Q3 Loss, Lags Revenue Estimates

Zacks
·
14 Nov 2024

BRIEF-Ocular Therapeutix Appoints Namrata Saroj, OD, As Chief Business Officer

Reuters
·
12 Nov 2024